vs

Side-by-side financial comparison of Life360, Inc. (LIF) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Tarsus Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($151.7M vs $146.0M, roughly 1.0× Life360, Inc.). Life360, Inc. runs the higher net margin — 88.8% vs -5.5%, a 94.3% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 26.4%). Life360, Inc. produced more free cash flow last quarter ($36.6M vs $13.0M). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 36.6%).

Life360, Inc. develops family-focused safety and connectivity platforms. Core offerings include real-time location sharing, emergency alerts, driving behavior analysis tools and identity theft protection. It serves consumer markets across North America, Europe and Asia-Pacific, with most revenue from tiered premium subscription plans.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

LIF vs TARS — Head-to-Head

Bigger by revenue
TARS
TARS
1.0× larger
TARS
$151.7M
$146.0M
LIF
Growing faster (revenue YoY)
TARS
TARS
+102.0% gap
TARS
128.4%
26.4%
LIF
Higher net margin
LIF
LIF
94.3% more per $
LIF
88.8%
-5.5%
TARS
More free cash flow
LIF
LIF
$23.6M more FCF
LIF
$36.6M
$13.0M
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
36.6%
LIF

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
LIF
LIF
TARS
TARS
Revenue
$146.0M
$151.7M
Net Profit
$129.7M
$-8.4M
Gross Margin
75.1%
Operating Margin
6.1%
-5.3%
Net Margin
88.8%
-5.5%
Revenue YoY
26.4%
128.4%
Net Profit YoY
1425.9%
63.8%
EPS (diluted)
$1.53
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LIF
LIF
TARS
TARS
Q4 25
$146.0M
$151.7M
Q3 25
$124.5M
$118.7M
Q2 25
$115.4M
$102.7M
Q1 25
$103.6M
$78.3M
Q4 24
$115.5M
$66.4M
Q3 24
$92.9M
$48.1M
Q2 24
$84.9M
$40.8M
Q1 24
$78.2M
$27.6M
Net Profit
LIF
LIF
TARS
TARS
Q4 25
$129.7M
$-8.4M
Q3 25
$9.8M
$-12.6M
Q2 25
$7.0M
$-20.3M
Q1 25
$4.4M
$-25.1M
Q4 24
$8.5M
$-23.1M
Q3 24
$7.7M
$-23.4M
Q2 24
$-11.0M
$-33.3M
Q1 24
$-9.8M
$-35.7M
Gross Margin
LIF
LIF
TARS
TARS
Q4 25
75.1%
Q3 25
78.0%
Q2 25
78.4%
Q1 25
80.6%
Q4 24
74.0%
Q3 24
75.4%
Q2 24
75.0%
Q1 24
76.7%
Operating Margin
LIF
LIF
TARS
TARS
Q4 25
6.1%
-5.3%
Q3 25
4.6%
-12.2%
Q2 25
1.7%
-21.6%
Q1 25
2.1%
-33.5%
Q4 24
4.9%
-36.8%
Q3 24
-5.3%
-52.3%
Q2 24
-2.8%
-81.6%
Q1 24
-8.2%
-136.5%
Net Margin
LIF
LIF
TARS
TARS
Q4 25
88.8%
-5.5%
Q3 25
7.9%
-10.6%
Q2 25
6.1%
-19.8%
Q1 25
4.2%
-32.1%
Q4 24
7.4%
-34.8%
Q3 24
8.3%
-48.7%
Q2 24
-12.9%
-81.6%
Q1 24
-12.5%
-129.4%
EPS (diluted)
LIF
LIF
TARS
TARS
Q4 25
$1.53
$-0.17
Q3 25
$0.11
$-0.30
Q2 25
$0.08
$-0.48
Q1 25
$0.05
$-0.64
Q4 24
$0.14
$-0.57
Q3 24
$0.09
$-0.61
Q2 24
$-0.15
$-0.88
Q1 24
$-0.14
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LIF
LIF
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$494.3M
$417.3M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$548.2M
$343.4M
Total Assets
$959.7M
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LIF
LIF
TARS
TARS
Q4 25
$494.3M
$417.3M
Q3 25
$455.7M
$401.8M
Q2 25
$432.7M
$381.1M
Q1 25
$168.9M
$407.9M
Q4 24
$159.2M
$291.4M
Q3 24
$159.0M
$317.0M
Q2 24
$160.8M
$323.6M
Q1 24
$73.4M
$298.5M
Total Debt
LIF
LIF
TARS
TARS
Q4 25
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Q1 24
$5.2M
$29.9M
Stockholders' Equity
LIF
LIF
TARS
TARS
Q4 25
$548.2M
$343.4M
Q3 25
$391.4M
$335.1M
Q2 25
$366.7M
$332.6M
Q1 25
$376.3M
$342.5M
Q4 24
$358.5M
$224.5M
Q3 24
$339.7M
$237.5M
Q2 24
$326.7M
$252.2M
Q1 24
$239.8M
$275.2M
Total Assets
LIF
LIF
TARS
TARS
Q4 25
$959.7M
$562.2M
Q3 25
$787.5M
$534.6M
Q2 25
$753.6M
$495.0M
Q1 25
$455.4M
$500.8M
Q4 24
$441.6M
$377.0M
Q3 24
$427.4M
$376.3M
Q2 24
$405.9M
$376.8M
Q1 24
$318.8M
$349.3M
Debt / Equity
LIF
LIF
TARS
TARS
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×
Q1 24
0.02×
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LIF
LIF
TARS
TARS
Operating Cash FlowLast quarter
$36.8M
$19.3M
Free Cash FlowOCF − Capex
$36.6M
$13.0M
FCF MarginFCF / Revenue
25.1%
8.6%
Capex IntensityCapex / Revenue
0.2%
4.2%
Cash ConversionOCF / Net Profit
0.28×
TTM Free Cash FlowTrailing 4 quarters
$86.8M
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LIF
LIF
TARS
TARS
Q4 25
$36.8M
$19.3M
Q3 25
$26.4M
$18.3M
Q2 25
$13.3M
$-29.4M
Q1 25
$12.1M
$-20.7M
Q4 24
$12.3M
$-22.2M
Q3 24
$6.3M
$-8.7M
Q2 24
$3.3M
$-14.4M
Q1 24
$10.7M
$-37.8M
Free Cash Flow
LIF
LIF
TARS
TARS
Q4 25
$36.6M
$13.0M
Q3 25
$25.6M
$16.3M
Q2 25
$12.7M
$-30.4M
Q1 25
$11.9M
$-21.2M
Q4 24
$11.2M
$-22.3M
Q3 24
$6.3M
$-8.9M
Q2 24
$3.2M
$-15.4M
Q1 24
$-38.0M
FCF Margin
LIF
LIF
TARS
TARS
Q4 25
25.1%
8.6%
Q3 25
20.6%
13.8%
Q2 25
11.0%
-29.6%
Q1 25
11.5%
-27.1%
Q4 24
9.7%
-33.5%
Q3 24
6.8%
-18.6%
Q2 24
3.8%
-37.8%
Q1 24
-137.5%
Capex Intensity
LIF
LIF
TARS
TARS
Q4 25
0.2%
4.2%
Q3 25
0.6%
1.6%
Q2 25
0.6%
1.0%
Q1 25
0.1%
0.8%
Q4 24
1.0%
0.1%
Q3 24
0.0%
0.6%
Q2 24
0.1%
2.5%
Q1 24
0.0%
0.6%
Cash Conversion
LIF
LIF
TARS
TARS
Q4 25
0.28×
Q3 25
2.70×
Q2 25
1.90×
Q1 25
2.75×
Q4 24
1.45×
Q3 24
0.83×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons